Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Joshua

Showing results (201-210 of 216) with videos related to

Pageof 22
Sort By:
Vision Research|January 22, 2008
Further mapping of 10q26 supports strong association of HTRA1 polymorphisms with age-related macular degenerationDaniel Gibbs, Zhenglin Yang, Ryan Constantine, et al.
Science (New York, N.Y.)|October 21, 2006
A variant of the HTRA1 gene increases susceptibility to age-related macular degenerationZhenglin Yang, Nicola J Camp, Hui Sun, et al.
Blood|March 1, 1996
A randomized study of high-dose cytarabine in induction in acute myeloid leukemiaJ F Bishop, J P Matthews, G A Young, et al.
Advances in Experimental Medicine and Biology|January 15, 2008
10q26 is associated with increased risk of age-related macular degeneration in the Utah populationD Joshua Cameron, Zhenglin Yang, Zhongzhong Tong, et al.
Leukemia|August 23, 2001
Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemiaK Bradstock, J Matthews, G Young, et al.
International Journal of Laboratory Hematology|August 12, 2008
Rule based processing of the CD4000, CD3200 and CD Sapphire analyser output using the Cerner Discern Expert ModuleP Burgess, H Robin, M Langshaw, et al.
Leukemia|December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVORW-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia|August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR studyP Moreau, D Joshua, W-J Chng, et al.
Leukemia|November 2, 2013
International Myeloma Working Group recommendations for global myeloma careH Ludwig, J S Miguel, M A Dimopoulos, et al.
Leukemia|July 21, 2006
International uniform response criteria for multiple myelomaB G M Durie, J-L Harousseau, J S Miguel, et al.
Pageof 22

Showing results (201-210 of 216) with videos related to

Sort By:
Pageof 22
Vision Research|January 22, 2008
Further mapping of 10q26 supports strong association of HTRA1 polymorphisms with age-related macular degenerationDaniel Gibbs, Zhenglin Yang, Ryan Constantine, et al.
Science (New York, N.Y.)|October 21, 2006
A variant of the HTRA1 gene increases susceptibility to age-related macular degenerationZhenglin Yang, Nicola J Camp, Hui Sun, et al.
Blood|March 1, 1996
A randomized study of high-dose cytarabine in induction in acute myeloid leukemiaJ F Bishop, J P Matthews, G A Young, et al.
Advances in Experimental Medicine and Biology|January 15, 2008
10q26 is associated with increased risk of age-related macular degeneration in the Utah populationD Joshua Cameron, Zhenglin Yang, Zhongzhong Tong, et al.
Leukemia|August 23, 2001
Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemiaK Bradstock, J Matthews, G Young, et al.
International Journal of Laboratory Hematology|August 12, 2008
Rule based processing of the CD4000, CD3200 and CD Sapphire analyser output using the Cerner Discern Expert ModuleP Burgess, H Robin, M Langshaw, et al.
Leukemia|December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVORW-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia|August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR studyP Moreau, D Joshua, W-J Chng, et al.
Leukemia|November 2, 2013
International Myeloma Working Group recommendations for global myeloma careH Ludwig, J S Miguel, M A Dimopoulos, et al.
Leukemia|July 21, 2006
International uniform response criteria for multiple myelomaB G M Durie, J-L Harousseau, J S Miguel, et al.
Pageof 22